AveXis (AVXS) IPO Opens Down 10%

Today's IPO for AveXis, Inc. (Nasdaq: AVXS) opened for trading at $18.02 after pricing 4,750,000 shares of common stock at an initial public offering price of $20 per share, the middle of the expected $19-$20 range. The offering size was lifted from 4,250,000 shares.

Goldman, Sachs & Co. and Jefferies LLC are acting as joint book-running managers. BMO Capital Markets Corp. is acting as lead manager and Chardan is acting as co-manager of the offering.

AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1.

You May Also Be Interested In

• Jersey Mike's files for IPO, plans NYSE listing under ticker JMKE
• ITG, Inc. raises $323.4M in Nasdaq IPO at $16 per share
• Viking Acquisition Corp. II prices $200M IPO on NYSE